Rocklage Scott M's Form 4 filing
Skye Bioscience, Inc. (SKYE) · filed Sep 24, 2026
- Accession no.
- 0001231919-26-001224
- Filed
- Sep 24, 2026, 4:29 PM ET
- Trade date
- Sep 22-23, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $239.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rocklage Scott MCIK 0001219014 | 10% Owner |
| Diekman John DCIK 0001240357 | 10% Owner |
| 5AM Ventures II LPCIK 0001386509 | 10% Owner |
| 5AM Co-Investors II LPCIK 0001390376 | 10% Owner |
| 5AM Partners II, LLCCIK 0001555952 | 10% Owner |
| Parmar KushCIK 0001664281 | 10% Owner |
| 5AM Ventures VII, L.P.CIK 0001844435 | 10% Owner |
| 5AM Partners VII, LLCCIK 0001873545 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Common Stock | SSaleDisposed | −27,612 | $1.65 | −$45,559.8 | 114,851 | Indirect | |
| Sep 22, 2026 | Common Stock | SSaleDisposed | −1,088 | $1.65 | −$1,795.2 | 4,528 | Indirect | |
| Sep 23, 2026 | Common Stock | SSaleDisposed | −114,851 | $1.61F3 | −$184,910.11 | 0 | Indirect | |
| Sep 23, 2026 | Common Stock | SSaleDisposed | −4,528 | $1.61F3 | −$7,290.08 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 2 transactions in Table I.